Related references
Note: Only part of the references are listed.Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection
Magnus Joakim Hansson et al.
CHEMISTRY & BIOLOGY (2015)
ANTI CAPSID DRUGS HAP12 AND AT130 TARGET HBV CORE PROTEIN NUCLEAR FUNCTIONS
L. Belloni et al.
DIGESTIVE AND LIVER DISEASE (2015)
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy
Edith Y. Ho et al.
HEPATOLOGY INTERNATIONAL (2015)
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B
Stephan Menne et al.
JOURNAL OF HEPATOLOGY (2015)
Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: A meta-analysis
Min Dai et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2015)
The Interface between Hepatitis B Virus Capsid Proteins Affects Self-Assembly, Pregenomic RNA Packaging, and Reverse Transcription
Zhenning Tan et al.
JOURNAL OF VIROLOGY (2015)
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
Daniel Shouval et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2015)
STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus
Fang Guo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Perrine Martin et al.
GUT (2015)
SCI-B-VAC IS SUPERIOR TO ENGERIX-B FOR PREVENTING HBV VERTICAL TRANSMISSION
N. Saed et al.
JOURNAL OF HEPATOLOGY (2014)
Immunotherapeutic interventions in chronic hepatitis B virus infection: A review
Li Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation
Meng Xue et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow
G. Baltayiannis et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-kB Activation, and Is Active in Patient-Derived Xenograft Models
Christopher A. Benetatos et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance
Thomas H. King et al.
PLOS ONE (2014)
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Julie Lucifora et al.
SCIENCE (2014)
Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study
Anuj Gaggar et al.
VACCINE (2014)
Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naive and tolerant mouse models
Houda Boukhebza et al.
VACCINE (2014)
Emerging antivirals for the treatment of hepatitis B
Xue-Yan Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments
Ceen-Ming Tang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
10th Annual Meeting of the Oligonucleotide Therapeutics Society San Diego, California October 12-15, 2014 Session Summaries|
Keith T. Gagnon et al.
NUCLEIC ACID THERAPEUTICS (2014)
Entry of hepatitis B and C viruses - recent progress and future impact
Thomas F. Baumert et al.
CURRENT OPINION IN VIROLOGY (2014)
Preclinical Characterization of GLS4, an Inhibitor of Hepatitis B Virus Core Particle Assembly
Guoyi Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
Jennifer L. Allensworth et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
BASIC AND TRANSLATIONAL-LIVER
Robert E. Lanford et al.
GASTROENTEROLOGY (2013)
The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus
Tassilo Volz et al.
JOURNAL OF HEPATOLOGY (2013)
Genetically Altering the Thermodynamics and Kinetics of Hepatitis B Virus Capsid Assembly Has Profound Effects on Virus Replication in Cell Culture
Zhenning Tan et al.
JOURNAL OF VIROLOGY (2013)
New Therapeutic Targets and Drugs for the Treatment of Chronic Hepatitis B
Simon P. Fletcher et al.
SEMINARS IN LIVER DISEASE (2013)
Assembly-Directed Antivirals Differentially Bind Quasiequivalent Pockets to Modify Hepatitis B Virus Capsid Tertiary and Quaternary Structure
Sarah P. Katen et al.
STRUCTURE (2013)
A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice
Pascale Buchmann et al.
VACCINE (2013)
The potential of 1018 ISS adjuvant in hepatitis B vaccines HEPLISAV™ review
Nelson F. Eng et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Alla Arzumanyan et al.
NATURE REVIEWS CANCER (2013)
In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations
Xue-Yan Wang et al.
ANTIVIRAL THERAPY (2012)
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
Miguel-Angel Perales et al.
BLOOD (2012)
Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection
Zheng Zhang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults
Scott A. Halperin et al.
VACCINE (2012)
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age
Scott A. Halperin et al.
VACCINE (2012)
Living in the liver: hepatic infections
Ulrike Protzer et al.
NATURE REVIEWS IMMUNOLOGY (2012)
HBV life cycle and novel drug targets
Daniel Grimm et al.
HEPATOLOGY INTERNATIONAL (2011)
Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy
J. -H. Jang et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?
Milan J. Sonneveld et al.
LIVER INTERNATIONAL (2011)
Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response
Haiyan Li et al.
NATURE NANOTECHNOLOGY (2011)
Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA/SCID Mice
Nicolas Brezillon et al.
PLOS ONE (2011)
Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro
Ted Bader et al.
ANTIVIRAL RESEARCH (2010)
The replication cycle of hepatitis B virus
Stephan Urban et al.
JOURNAL OF HEPATOLOGY (2010)
PRECLINICAL STUDIES ON MYRCLUDEX B, A NOVEL ENTRY INHIBITOR FOR HEPATITS B- AND HEPATITIS DELTA VIRUS (HDV) INFECTIONS
S. Urban et al.
JOURNAL OF HEPATOLOGY (2010)
Hepatitis B treatment: Current best practices, avoiding resistance
R. G. GISH
CLEVELAND CLINIC JOURNAL OF MEDICINE (2009)
Long-Term Therapy with Clevudine for Chronic Hepatitis B Can Be Associated with Myopathy Characterized by Depletion of Mitochondrial DNA
Jung Im Seok et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
EASL Clinical Practice Guidelines
Jean-Michel Pawlotsky
JOURNAL OF HEPATOLOGY (2009)
PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen
Ulla B. Hellstrom et al.
VIROLOGY JOURNAL (2009)
LB80380: a promising new drug for the treatment of chronic hepatitis B
James Fung et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues
Nancy Leung
HEPATOLOGY INTERNATIONAL (2008)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2008)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular and cellular signatures of human vaccine adjuvants
F. Mosca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging
J. J. Feld et al.
ANTIVIRAL RESEARCH (2007)
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression
Byung Chul Yoo et al.
HEPATOLOGY (2007)
Immunopathogenesis of hepatitis B virus infection
J. Judy Chang et al.
IMMUNOLOGY AND CELL BIOLOGY (2007)
BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly
Stephen J. Stray et al.
JOURNAL OF MOLECULAR RECOGNITION (2006)
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B
HS Lee et al.
HEPATOLOGY (2006)
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
TT Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
CL Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly
SJ Stray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen
JC Aguilar et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
G Fattovich et al.
GASTROENTEROLOGY (2004)
Lamivudine for patients with chronic hepatitis B and advanced liver disease
YF Liaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease
T Weinstein et al.
NEPHRON CLINICAL PRACTICE (2004)
Vaccine adjuvants: Current state and future trends
N Petrovsky et al.
IMMUNOLOGY AND CELL BIOLOGY (2004)
Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
WGE Cooksley et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids
K Deres et al.
SCIENCE (2003)
Results of lamivudine trials in Asia
YF Liaw
JOURNAL OF HEPATOLOGY (2003)
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro
WE Delaney et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Genetic variability in hepatitis B viruses
K Kidd-Ljunggren et al.
JOURNAL OF GENERAL VIROLOGY (2002)
IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation
CL Mackall et al.
BLOOD (2001)
Rapid seroprotection against hepatitis B following the first dose of a Pre-S-1/Pre-S-2/S vaccine
MY Shapira et al.
JOURNAL OF HEPATOLOGY (2001)
Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
Share Paper
